EnhancedFasL Soluble (human) (rec.) Pack
Product Code:
AG-44B-0001
AG-44B-0001
Regulatory Status:
RUO
RUO
Target Species:
- Human
- Mouse
Shipping:
Blue Ice
Blue Ice
Storage:
-20°C
-20°C
No additional charges, what you see is what you pay! *
| Code | Size | Price |
|---|
| AG-44B-0001-KI01 | 1 Set | £420.00 |
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: Switzerland.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
Typical lead time: 7-10 working days.
Contact us for more accurate information.
- Further Information
- Documents
- References
- Show All
Further Information
Alternate Names/Synonyms:
APO-1L; CD95L; CD178; TNFSF 6; Fas Ligand
EClass:
32160000
Handling Advice:
After reconstitution, prepare aliquots and store at -20°C.Avoid freeze/thaw cycles.
Kit Contains:
1x10µg of FasL, Soluble (human) (rec.) (Prod. No. AG-40B-0001) | 4x50µg of TNF Ligands Enhancer (Prod. No. AG-35B-0001)
Long Description:
Set. FasL, Soluble (human) (rec. ) induces apoptosis in a concentration range of <1ng/ml in the presence of 0. 1 to 1µg/ml of TNF Ligands Enhancer (Prod. No. AG-35B-0001). (Optimal conditions must be determined individually for each cell line tested)
Other data:
Source/Host: Produced in HEK 293 cells. A FLAG®-tag is fused at the N-terminus of the extracellular domain of human FasL (aa 103-281). Concentration: FasL: 0.1mg/ml after reconstitution TNF Ligands Enhancer: 1mg/ml after reconstitution Purity: >95% (SDS-PAGE)Formulation: Lyophilized. Contains PBS. Endotoxin Content: FasL: <0.05EU/µg purified protein (LAL test; Lonza). TNF Ligands Enhancer: <0.01EU/µg purified protein (LAL test; Lonza). Reconstitution: FasL: reconstitute with 100µl sterile water. PBS containing at least 0.1% BSA should be used for further dilutions. TNF Ligands Enhancer: reconstitute each vial with 50µl sterile water. PBS containing at least 0.1% BSA should be used for further dilutions.
Package Type:
Plastic Vial
Product Description:
FasL, Soluble (human) (rec.) induces apoptosis in a concentration range of <1ng/ml in the presence of 0.1 to 1µg/ml of TNF Ligands Enhancer (Prod. No. AG-35B-0001). (Optimal conditions must be determined individually for each cell line tested)
Specificity:
Binds to human and mouse Fas (CD95; APO-1). Induces apoptosis of human Jurkat T cells at a concentration of <1ng/ml.
Transportation:
Non-hazardous
UNSPSC Category:
General Purpose Cell Biology Kits
UNSPSC Number:
41116111
Use & Stability:
Stable for at least 6 months after receipt when stored at -20°C.
Documents
References
Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-x(L): D.C. Huang, et al.; PNAS 96, 14871 (1999) | Fas ligand-induced c-Jun kinase activation in lymphoid cells requires extensive receptor aggregation but is independent of DAXX, and Fas-mediated cell death does not involve DAXX, RIP, or RAIDD: A. Villunger, et al.; J. Immunol. 165, 1337 (2000) | Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses: M. Rescigno, et al.; J. Exp. Med. 192, 1661 (2000) | NF-kappaB signals induce the expression of c-FLIP: O. Micheau, et al.; Mol. Cell. Biol. 21, 5299 (2001) | Potentiation of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas: P. Legembre, et al.; Cell Death Differ. 9, 329 (2002) | Multiple pathways of TWEAK-induced cell death: M. Nakayama, et al.; J. Immunol. 168, 734 (2002) | Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand: G. Lu, et al.; J. Immunol. 168, 1831 (2002) | Induction of apoptosis in malignant pleural mesothelioma cells by activation of the Fas (Apo-1/CD95) death-signal pathway: J.H. 4th Stewart et al.; J. Thorac. Cardiovasc. Surg. 123, 295 (2002) | Hepatic natural killer cells exclusively kill splenic/blood natural killer-resistant tumor cells by the perforin/granzyme pathway: D. Vermijlen, et al.; J. Leukoc. Biol. 72, 668 (2002) | Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8: M.R. Sprick, et al.; EMBO J. 21, 4520 (2002) | An essential role for membrane rafts in the initiation of Fas/CD95-triggered cell death in mouse thymocytes: A.O. Hueber, et al.; EMBO Rep. 3, 190 (2002) | Cutting edge: SDS-stable Fas microaggregates: an early event of Fas activation occurring with agonistic anti-Fas antibody but not with Fas ligand: P. Legembre, et al.; J. Immunol. 171, 5659 (2003) | The role of p53 and Fas in a model of acute murine graft-versus-host disease: S. Yada, et al.; J. Immunol. 174, 1291 (2005) | CD1d-unrestricted human NKT cells release chemokines upon Fas engagement: M. Giroux & F. Denis; Blood 105, 703 (2005) | Amplification of CD95 activation by caspase 8-induced endosomal acidification in rat hepatocytes: R. Reinehr, et al.; J. Biol. Chem. 283, 2211 (2008)